Ofatumumab vs Ublituximab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: CD20 · full Multiple Sclerosis pipeline

Ofatumumab

Marketed by Novartis and partners

Approved in Multiple Sclerosismonoclonal antibody
Reliable signal

NCT02792231 · Phase 3 · completed

This was a large, randomized, quadruple-blind, active-controlled trial of 955 participants, comparing ofatumumab with teriflunomide. The prespecified primary clinical endpoint, annualized confirmed relapse rate, was significantly better with ofatumumab (p<0.001), supporting a strong evidence grade despite mixed findings for some secondary measures.

Next expected readout: April 2027 · NCT05090371 (registry estimate)

Reported efficacy

Annualized Relapse Rate (ARR) (Baseline up to 2.5 years): Annualized Relapse Rate (ASCLEPIOS II): 0.10 (ofatumumab) vs 0.25 (teriflunomide); difference -0.15 (95% CI: -0.20, -0.09) (met)

Result source: NCT02792231

Ublituximab · Briumvi

Marketed by TG THERAPEUTICS, INC. and partners

Approved in Multiple Sclerosismonoclonal antibody
Reliable signal

NCT03277261 · Phase 3 · completed

This was a randomized, quadruple-masked, active-controlled trial of 549 participants, with ublituximab and teriflunomide administered alongside matching placebos. The primary clinical endpoint was met: ublituximab produced a significantly lower annualized relapse rate than teriflunomide through 96 weeks (p<0.0001).

Next expected readout: January 2027 · NCT05877963 (registry estimate)

Reported efficacy

Annualized Relapse Rate (ARR) (Up to 96 weeks): Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.091 relapses per participant-years (95% CI 0.049 to 0.169) vs Teriflunomide + IV Placebo 0.178 relapses per participant-years (95% CI 0.109 to 0.291) (met)

Result source: NCT03277248

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOfatumumabUblituximab
Annualised relapse rate0.1 vs 0.3vs TER20 mg · n 469NCT02792231
4 other results
  • 0.1 vs 0.2 20 mg · n 454 · Phase 3 · primary NCT02792218
  • 0.1 vs 0.2 20 mg · n 461 · Phase 3 · secondary NCT02792231
  • 0.1 vs 0.2 20 mg · n 453 · Phase 3 · secondary NCT02792218
  • 0.3 vs 0.6 20 mg · wk 24 · n 43 · Phase 2 · secondary NCT03249714
0.1 vs 0.2vs Teriflunomidewk 96 · n 271NCT03277261
1 other result
  • 0.1 vs 0.2 wk 96 · n 272 · Phase 3 · primary NCT03277248
Free of 3-month confirmed disability progression (%)—Not posted · NCT04788615—Trial running · NCT07220252
New or enlarging T2 lesions—Not posted · NCT04788615—Trial running · NCT07220252

Annualised relapse rate

Ofatumumab
0.1 vs 0.3vs TER20 mg · n 469NCT02792231
4 other results
  • 0.1 vs 0.2 20 mg · n 454 · Phase 3 · primary NCT02792218
  • 0.1 vs 0.2 20 mg · n 461 · Phase 3 · secondary NCT02792231
  • 0.1 vs 0.2 20 mg · n 453 · Phase 3 · secondary NCT02792218
  • 0.3 vs 0.6 20 mg · wk 24 · n 43 · Phase 2 · secondary NCT03249714
Ublituximab
0.1 vs 0.2vs Teriflunomidewk 96 · n 271NCT03277261
1 other result
  • 0.1 vs 0.2 wk 96 · n 272 · Phase 3 · primary NCT03277248

Free of 3-month confirmed disability progression (%)

Ofatumumab
—Not posted · NCT04788615
Ublituximab
—Trial running · NCT07220252

New or enlarging T2 lesions

Ofatumumab
—Not posted · NCT04788615
Ublituximab
—Trial running · NCT07220252
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Ofatumumab: 6 of 6 rows · Ublituximab: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOfatumumab
Rows use multiple source trials
Ublituximab
Rows use multiple source trials
Annualized Relapse
event rate · per year
No placebo or comparator arm
0.06 per yeara,b,c,d
NCT04353492 · Phase 3 · registry result, not featured evidence
0.28 per year @ 48wke,a,b,c,d
NCT02738775 · Phase 2 · registry result, not featured evidence
show 5 more doses
0 per year @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0.14 per year @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0.14 per year @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 per year @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 per year @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
NEDA
responder rate · % of participants
9.8% (n=433) vs 5.1% (n=427) TER @ 104wk20 mgb,c,f
NCT02792231 · Phase 3
1 other source trial
14.4% (n=428) vs 3.2% (n=413) TER @ 104wk20 mg
NCT02792218 · Phase 3
44.6% (n=271) vs 15% (n=274) Teriflunomide @ 96wkb,c,f
NCT03277261 · Phase 3 · combination
1 other source trial
43% (n=272) vs 11.4% (n=272) Teriflunomide @ 96wk
NCT03277248 · Phase 3 · combination
Dropout rate
17%20 mgg
NCT02792231 · Phase 3
show 26 more results
—20mg
NCT02792231 · Phase 3
10.5%20 mg
NCT02792218 · Phase 3
—20 mg
NCT02792218 · Phase 3
19.8%20 mg
NCT04486716 · Phase 3
2.9%60 mg q12w
NCT01457924 · Phase 2
9.4%60 mg q4w
NCT01457924 · Phase 2
6.3%30 mg q12w
NCT01457924 · Phase 2
14.7%3 mg q12w
NCT01457924 · Phase 2
0%700 mg
NCT00640328 · Phase 2 · monotherapy
9.1%300 mg
NCT00640328 · Phase 2 · monotherapy
0%100 mg
NCT00640328 · Phase 2 · monotherapy
7.6%Ofatumumab
NCT05084638 · Phase 4 · registry result, not featured evidence
—Ofatumumab-Treated
NCT05084638 · Phase 4 · registry result, not featured evidence
4%
NCT05199571 · Phase 4 · registry result, not featured evidence
—20 mg
NCT04353492 · Phase 3 · registry result, not featured evidence
6.9%Ofatumumab
NCT04353492 · Phase 3 · registry result, not featured evidence
7%20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0.8%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
12.4%g
NCT03277261 · Phase 3 · combination
show 7 more results
6.6%
NCT03277248 · Phase 3 · combination
0%Cohort 1
NCT02738775 · Phase 2 · registry result, not featured evidence
25%Cohort 2
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 3
NCT02738775 · Phase 2 · registry result, not featured evidence
11.1%Cohort 4
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 5
NCT02738775 · Phase 2 · registry result, not featured evidence
12.5%Cohort 6
NCT02738775 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.1%20 mgg
NCT02792231 · Phase 3
show 26 more results
—20mg
NCT02792231 · Phase 3
3.2%20 mg
NCT02792218 · Phase 3
—20 mg
NCT02792218 · Phase 3
4.5%20 mg
NCT04486716 · Phase 3
0%60 mg q12w
NCT01457924 · Phase 2
3.1%60 mg q4w
NCT01457924 · Phase 2
3.1%30 mg q12w
NCT01457924 · Phase 2
11.8%3 mg q12w
NCT01457924 · Phase 2
0%700 mg
NCT00640328 · Phase 2 · monotherapy
9.1%300 mg
NCT00640328 · Phase 2 · monotherapy
0%100 mg
NCT00640328 · Phase 2 · monotherapy
—Ofatumumab
NCT05084638 · Phase 4 · registry result, not featured evidence
—Ofatumumab-Treated
NCT05084638 · Phase 4 · registry result, not featured evidence
—
NCT05199571 · Phase 4 · registry result, not featured evidence
—20 mg
NCT04353492 · Phase 3 · registry result, not featured evidence
0.5%Ofatumumab
NCT04353492 · Phase 3 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0.8%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
6.2%g
NCT03277261 · Phase 3 · combination
show 7 more results
1.1%
NCT03277248 · Phase 3 · combination
0%Cohort 1
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 2
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 3
NCT02738775 · Phase 2 · registry result, not featured evidence
11.1%Cohort 4
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 5
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 6
NCT02738775 · Phase 2 · registry result, not featured evidence
Serious AEs
—20 mgg
NCT02792231 · Phase 3
show 26 more results
8.7%20mg
NCT02792231 · Phase 3
—20 mg
NCT02792218 · Phase 3
11%20 mg
NCT02792218 · Phase 3
5.9%20 mg
NCT04486716 · Phase 3
2.9%60 mg q12w
NCT01457924 · Phase 2
6.3%60 mg q4w
NCT01457924 · Phase 2
0%30 mg q12w
NCT01457924 · Phase 2
2.9%3 mg q12w
NCT01457924 · Phase 2
0%700 mg
NCT00640328 · Phase 2 · monotherapy
18.2%300 mg
NCT00640328 · Phase 2 · monotherapy
0%100 mg
NCT00640328 · Phase 2 · monotherapy
—Ofatumumab
NCT05084638 · Phase 4 · registry result, not featured evidence
6.7%Ofatumumab-Treated
NCT05084638 · Phase 4 · registry result, not featured evidence
0%
NCT05199571 · Phase 4 · registry result, not featured evidence
6%20 mg
NCT04353492 · Phase 3 · registry result, not featured evidence
—Ofatumumab
NCT04353492 · Phase 3 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
2.5%20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
2.3%20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
1.6%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
3.1%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
11.4%g
NCT03277261 · Phase 3 · combination
show 7 more results
10.3%
NCT03277248 · Phase 3 · combination
0%Cohort 1
NCT02738775 · Phase 2 · registry result, not featured evidence
12.5%Cohort 2
NCT02738775 · Phase 2 · registry result, not featured evidence
25%Cohort 3
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 4
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 5
NCT02738775 · Phase 2 · registry result, not featured evidence
25%Cohort 6
NCT02738775 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
20mgg
injection related reaction 24.7%
injection related reaction 24.7%
nasopharyngitis 18.3%
NCT02792231 · Phase 3
show 18 more results
20 mg
nasopharyngitis 17.6%
injection related reaction 15.9%
headache 12.7%
NCT02792218 · Phase 3
20 mg
covid-19 30.4%
fatigue 11.8%
headache 11.8%
NCT04486716 · Phase 3
60 mg q12w
injection related reaction 50%
nasopharyngitis 20.6%
fatigue 5.9%
NCT01457924 · Phase 2
60 mg q4w
injection related reaction 65.6%
nasopharyngitis 10.9%
headache 9.4%
NCT01457924 · Phase 2
30 mg q12w
injection related reaction 40.6%
nasopharyngitis 12.5%
fatigue 9.4%
NCT01457924 · Phase 2
3 mg q12w
injection related reaction 47.1%
urinary tract infection 8.8%
anaemia 5.9%
NCT01457924 · Phase 2
700 mg
rash 57.1% (placebo 50%)
throat irritation 28.6% (placebo 0%)
upper respiratory tract infection 28.6% (placebo 75%)
NCT00640328 · Phase 2 · monotherapy
300 mg
throat irritation 36.4% (placebo 0%)
rash 27.3% (placebo 50%)
viral infection 27.3% (placebo 0%)
NCT00640328 · Phase 2 · monotherapy
100 mg
nasopharyngitis 50% (placebo 25%)
throat irritation 37.5% (placebo 0%)
depression 25% (placebo 0%)
NCT00640328 · Phase 2 · monotherapy
chills 36.1%
headache 27.7%
myalgia 26.1%
NCT05084638 · Phase 4 · registry result, not featured evidence
injection related reaction 43.4%
covid-19 12.1%
upper respiratory tract infection 12.1%
NCT05199571 · Phase 4 · registry result, not featured evidence
20 mg
injection related reaction 53.4%
covid-19 37%
nasopharyngitis 17.1%
NCT04353492 · Phase 3 · registry result, not featured evidence
20 mg
nasopharyngitis 17.5% (placebo 19%)
rash 7.5% (placebo 0%)
alanine aminotransferase increased 5% (placebo 4.8%)
NCT03249714 · Phase 2 · registry result, not featured evidence
20 mg
injection related reaction 20.9% (placebo 19%)
nasopharyngitis 14% (placebo 19%)
oral herpes 9.3% (placebo 0%)
NCT03249714 · Phase 2 · registry result, not featured evidence
20 mg
injection related reaction 32%
headache 10.2%
injection site reaction 8.6%
NCT03560739 · Phase 2 · registry result, not featured evidence
20 mg
injection related reaction 38.5%
diarrhoea 7.7%
fatigue 7.7%
NCT03560739 · Phase 2 · registry result, not featured evidence
20 mg
injection related reaction 46.2%
asthenia 7.7%
cough 7.7%
NCT03560739 · Phase 2 · registry result, not featured evidence
20 mg
injection related reaction 22.3%
injection site reaction 13.1%
headache 5.4%
NCT03560739 · Phase 2 · registry result, not featured evidence
g
headache 30.8%
pyrexia 15%
nasopharyngitis 12.5%
NCT03277261 · Phase 3 · combination
show 7 more results
headache 37.9%
nasopharyngitis 24.6%
back pain 12.9%
NCT03277248 · Phase 3 · combination
back pain 37.5% (placebo 0%)
headache 25% (placebo 15.4%)
hypoaesthesia 25% (placebo 7.7%)
NCT02738775 · Phase 2 · registry result, not featured evidence
dizziness 37.5% (placebo 23.1%)
fatigue 37.5% (placebo 38.5%)
headache 37.5% (placebo 15.4%)
NCT02738775 · Phase 2 · registry result, not featured evidence
arthralgia 25% (placebo 7.7%)
diarrhoea 25% (placebo 0%)
fatigue 25% (placebo 38.5%)
NCT02738775 · Phase 2 · registry result, not featured evidence
fatigue 50% (placebo 38.5%)
nasopharyngitis 37.5% (placebo 0%)
sinusitis 37.5% (placebo 15.4%)
NCT02738775 · Phase 2 · registry result, not featured evidence
dysphagia 37.5% (placebo 15.4%)
infusion related reaction 37.5% (placebo 23.1%)
throat irritation 37.5% (placebo 15.4%)
NCT02738775 · Phase 2 · registry result, not featured evidence
nausea 62.5% (placebo 15.4%)
dizziness 37.5% (placebo 23.1%)
fatigue 37.5% (placebo 38.5%)
NCT02738775 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fAssessment timepoints differ: 104 weeks versus 96 weeks.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ofatumumab

Confirmed Disability Progression 9.4% (n=944) vs 13.5% (n=932) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 17 more results
10.9% (n=944) vs 15% (n=932) TER @ 104wk20 mg
NCT02792231 · Phase 3
9.3% (n=479) vs 13.2% (n=473) TER @ 78wk20 mg
NCT02792231 · Phase 3
10.5% (n=479) vs 14.6% (n=473) TER @ 104wk20 mg
NCT02792231 · Phase 3
9.4% (n=944) vs 13.5% (n=932) TER @ 78wk20 mg
NCT02792231 · Phase 3
10.9% (n=944) vs 15% (n=932) TER @ 104wk20 mg
NCT02792231 · Phase 3
9.4% (n=944) vs 13.5% (n=932) TER @ 78wk20 mg
NCT02792218 · Phase 3
10.9% (n=944) vs 15% (n=932) TER @ 104wk20 mg
NCT02792218 · Phase 3
9.4% (n=465) vs 13.9% (n=459) TER @ 78wk20 mg
NCT02792218 · Phase 3
11.3% (n=465) vs 15.4% (n=459) TER @ 104wk20 mg
NCT02792218 · Phase 3
7.8% (n=944) vs 10.7% (n=932) TER @ 78wk20 mg
NCT02792218 · Phase 3
8.1% (n=944) vs 12% (n=932) TER @ 104wk20 mg
NCT02792218 · Phase 3
7.5% (n=465) vs 11.5% (n=459) TER @ 78wk20 mg
NCT02792218 · Phase 3
8.2% (n=465) vs 13% (n=459) TER @ 104wk20 mg
NCT02792218 · Phase 3
9.4% (n=944) vs 13.5% (n=932) TER @ 78wk20 mg
NCT02792218 · Phase 3
10.9% (n=944) vs 15% (n=932) TER @ 104wk20 mg
NCT02792218 · Phase 3
7.8% (n=944) vs 10.7% (n=932) TER @ 78wk20 mg
NCT02792218 · Phase 3
8.1% (n=944) vs 12% (n=932) TER @ 104wk20 mg
NCT02792218 · Phase 3
Sustained Disability Progression 7.8% (n=944) vs 10.7% (n=932) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 5 more results
8.1% (n=944) vs 12% (n=932) TER @ 104wk20 mg
NCT02792231 · Phase 3
8% (n=479) vs 10% (n=473) TER @ 78wk20 mg
NCT02792231 · Phase 3
8% (n=479) vs 10.9% (n=473) TER @ 104wk20 mg
NCT02792231 · Phase 3
7.8% (n=944) vs 10.7% (n=932) TER @ 78wk20 mg
NCT02792231 · Phase 3
8.1% (n=944) vs 12% (n=932) TER @ 104wk20 mg
NCT02792231 · Phase 3
Sustained Reduction of Disability 10.1% (n=749) vs 7.6% (n=724) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 11 more results
11% (n=749) vs 8.2% (n=724) TER @ 104wk20 mg
NCT02792231 · Phase 3
11.1% (n=374) vs 8.1% (n=361) TER @ 78wk20 mg
NCT02792231 · Phase 3
12.3% (n=374) vs 8.1% (n=361) TER @ 104wk20 mg
NCT02792231 · Phase 3
5.4% (n=749) vs 4.6% (n=724) TER @ 78wk20 mg
NCT02792231 · Phase 3
5.8% (n=749) vs 4.6% (n=724) TER @ 104wk20 mg
NCT02792231 · Phase 3
10.1% (n=749) vs 7.6% (n=724) TER @ 78wk20 mg
NCT02792218 · Phase 3
11% (n=749) vs 8.2% (n=724) TER @ 104wk20 mg
NCT02792218 · Phase 3
9.1% (n=375) vs 7.1% (n=363) TER @ 78wk20 mg
NCT02792218 · Phase 3
9.7% (n=375) vs 8.2% (n=363) TER @ 104wk20 mg
NCT02792218 · Phase 3
5.4% (n=749) vs 4.6% (n=724) TER @ 78wk20 mg
NCT02792218 · Phase 3
5.8% (n=749) vs 4.6% (n=724) TER @ 104wk20 mg
NCT02792218 · Phase 3
T1 Gadolinium Enhancing Lesion 0.0317 vs 0.5172 TER per scan20 mg
event count · per scan
NCT02792231 · Phase 3
show 1 more result
0.067 vs 1.0413 placebo per scan @ 24wk20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
Annualized New or Enlarging T2 Lesion 0.94 vs 4.41 TER per year @ 52wk20 mg
event rate · per year
NCT02792231 · Phase 3
show 6 more results
0.72 vs 3.72 TER per year @ 104wk20 mg
NCT02792231 · Phase 3
0.13 vs 3.84 TER per year20 mg
NCT02792231 · Phase 3
1.13 vs 4.3 TER per year @ 52wk20 mg
NCT02792218 · Phase 3
0.72 vs 3.21 TER per year @ 104wk20 mg
NCT02792218 · Phase 3
0.05 vs 3.73 TER per year20 mg
NCT02792218 · Phase 3
3.7344 vs 13.1533 placebo per year @ 24wk20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
Annualized New or Enlarging T2 Lesion 0.64 vs 4.16 TER per year20 mg
event rate · per year
EOS n=448,442
NCT02792231 · Phase 3
Brain Volume Loss -0.29% (n=437) vs -0.35% (n=433) TER20 mg
percent change · % of baseline
NCT02792231 · Phase 3
show 1 more result
-0.28% (n=418) vs -0.35% (n=408) TER20 mg
NCT02792218 · Phase 3
Relapsed Subjects 16.51% (n=469) vs 32.68% (n=470) TER20 mg
responder rate · % of participants
NCT02792231 · Phase 3
SDMT Impairment 14.3% (n=930) vs 13.7% (n=917) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 3 more results
15.4% (n=930) vs 14% (n=917) TER @ 104wk20 mg
NCT02792231 · Phase 3
14.3% (n=930) vs 13.7% (n=917) TER @ 78wk20 mg
NCT02792218 · Phase 3
15.4% (n=930) vs 12.4% (n=917) TER @ 104wk20 mg
NCT02792218 · Phase 3
Clinical Worsening 20.5% (n=941) vs 21.7% (n=930) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 3 more results
21.4% (n=941) vs 22.6% (n=930) TER @ 104wk20 mg
NCT02792231 · Phase 3
20.5% (n=941) vs 21.7% (n=930) TER @ 78wk20 mg
NCT02792218 · Phase 3
21.4% (n=941) vs 22.6% (n=930) TER @ 104wk20 mg
NCT02792218 · Phase 3
SDMT 1.02 vs 0.64 TER score @ 26wk20 mg
absolute change · score
NCT02792231 · Phase 3
show 9 more results
1.82 vs 1.7 TER score @ 52wk20 mg
NCT02792231 · Phase 3
2.84 vs 2.05 TER score @ 78wk20 mg
NCT02792231 · Phase 3
3.5 vs 2.39 TER score @ 104wk20 mg
NCT02792231 · Phase 3
3.53 vs 2.97 TER score @ 130wk20 mg
NCT02792231 · Phase 3
1.02 vs 0.64 TER score @ 26wk20 mg
NCT02792218 · Phase 3
1.82 vs 1.7 TER score @ 52wk20 mg
NCT02792218 · Phase 3
2.84 vs 2.05 TER score @ 78wk20 mg
NCT02792218 · Phase 3
3.5 vs 2.39 TER score @ 104wk20 mg
NCT02792218 · Phase 3
2.97 vs 2.97 TER score @ 130wk20 mg
NCT02792218 · Phase 3
T25FW 20% Worsening 11% (n=936) vs 10.4% (n=925) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 3 more results
11.4% (n=936) vs 10.6% (n=925) TER @ 104wk20 mg
NCT02792231 · Phase 3
11% (n=936) vs 10.4% (n=925) TER @ 78wk20 mg
NCT02792218 · Phase 3
11.4% (n=936) vs 10.6% (n=925) TER @ 104wk20 mg
NCT02792218 · Phase 3

+ 23 further endpoints in the CSV export.

Ublituximab

New and Enlarging T2 Lesion 0.213% (n=260) vs 2.789% (n=267) Teriflunomide @ 96wk
event count · % of participants
NCT03277261 · Phase 3 · combination
show 1 more result
0.282% (n=269) vs 2.831% (n=259) Teriflunomide
NCT03277248 · Phase 3 · combination
Time to CDP NA vs NA Teriflunomide months @ 96wk
time to event · months
NCT03277261 · Phase 3 · combination
show 1 more result
NA vs NA Teriflunomide months @ 96wk
NCT03277248 · Phase 3 · combination
Impaired SDMT 29.2% (n=271) vs 31.8% (n=274) Teriflunomide @ 96wk
responder rate · % of participants
NCT03277261 · Phase 3 · combination
show 1 more result
29% (n=272) vs 31.6% (n=272) Teriflunomide @ 96wk
NCT03277248 · Phase 3 · combination
Brain Volume -0.197% (n=204) vs -0.125% (n=207) Teriflunomide @ 96wk
percent change · % of baseline
NCT03277261 · Phase 3 · combination
show 1 more result
-0.194% (n=235) vs -0.176% (n=224) Teriflunomide @ 96wk
NCT03277248 · Phase 3 · combination
Gd-enhancing T1 Lesion 0.009% (n=272) vs 0.25% (n=267) Teriflunomide
event count · % of participants
NCT03277248 · Phase 3 · combination
New Gadolinium Enhancing T1 Lesion Count Per Scan 0 lesions @ 24wk
event count · lesions
No placebo or comparator arm
NCT02738775 · Phase 2 · registry result, not featured evidence
show 11 more results
0 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
New or Enlarging T2 Lesion 0.38 lesions @ 24wk
event count · lesions
No placebo or comparator arm
NCT02738775 · Phase 2 · registry result, not featured evidence
show 11 more results
0.29 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0.25 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0.14 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0.25 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
Relapse Free 75% (n=8) @ 48wk
responder rate · % of participants
No placebo or comparator arm
NCT02738775 · Phase 2 · registry result, not featured evidence
show 5 more results
100% (n=8) @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
87.5% (n=8) @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
87.5% (n=8) @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
100% (n=8) @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
100% (n=8) @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ofatumumab's landscape · Ublituximab's landscape